Financings & Placements: Anadys Pharmaceuticals Eyes $12.5 Million Raise

June 1, 2010 (FinancialWire) — Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) said that it has entered into definitive agreements with certain institutional investors to raise around $12.5 million in gross proceeds in a "registered direct" offering through the sale of a total of 5,813,954 shares of its common stock at an offering price of $2.15 per share.

Anadys estimates that net proceeds from the offering will be around $11.3 million. The closing of the transaction is scheduled to occur on June 1.

The company said it will use the proceeds from the transaction for general corporate purposes.

California-based Anadys Pharmaceuticals is a biopharmaceutical company focused on developing novel medicines for the treatment of hepatitis C.

The company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. In an ongoing Phase II study, the company has completed 12 weeks of dosing ANA598 added to current standard of care.

Anadys has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [fnncngj] [btnwswntb]